https://www.biospace.com/nextgen NextGen: Class of 2026 en-US Fri, 26 Jun 2026 21:25:24 GMT https://www.biospace.com/press-releases/stonegate-updates-coverage-on-burcon-nutrascience-corporation-bu-4q26 Fri, 26 Jun 2026 21:25:24 GMT https://www.biospace.com/press-releases/stonegate-updates-coverage-on-burcon-nutrascience-corporation-bu-4q26 https://www.biospace.com/business/sky-high-parabilis-kailera-ipos-spur-optimism-but-only-for-derisked-biotechs Annalee Armstrong Biotechs are benefitting from the AI tech frenzy and inflation, but validated pipelines and careful planning are still key to the recent record-setting IPOs, experts say. Thu, 11 Jun 2026 13:44:20 GMT https://www.biospace.com/business/sky-high-parabilis-kailera-ipos-spur-optimism-but-only-for-derisked-biotechs https://www.biospace.com/business/facing-pressure-from-china-biospaces-nextgen-biotech-leaders-say-bring-it-on Annalee Armstrong From Chinese innovation to AI, biotech CEOs are being hit with challenges at a breakneck pace. Three leaders from BioSpace’s NextGen Class of 2026 told us about the issues keeping them up at night. Wed, 03 Jun 2026 04:18:00 GMT https://www.biospace.com/business/facing-pressure-from-china-biospaces-nextgen-biotech-leaders-say-bring-it-on https://www.biospace.com/drug-development/apogee-investors-riled-by-1-3b-royalty-deal-as-eczema-drug-matches-lillys-ebglyss Annalee Armstrong Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone. Wed, 27 May 2026 15:15:18 GMT https://www.biospace.com/drug-development/apogee-investors-riled-by-1-3b-royalty-deal-as-eczema-drug-matches-lillys-ebglyss https://www.biospace.com/drug-development/kardigan-blood-pressure-drug-proves-hypothesis-despite-split-phase-2-readout Annalee Armstrong While tonlamarsen missed one of two co-primary endpoints, Kardigan says the drug has shown a clinically meaningful effect on blood pressure, supporting advancement into Phase 2b. Mon, 30 Mar 2026 13:46:00 GMT https://www.biospace.com/drug-development/kardigan-blood-pressure-drug-proves-hypothesis-despite-split-phase-2-readout https://www.biospace.com/fda/prasad-out-at-fda-lawmaker-takes-action-on-rare-disease-rejections-and-a-spate-of-obesity-data Heather McKenzie Annalee Armstrong Jef Akst Rare disease biotech stocks pop on the news that Vinay Prasad, the FDA’s chief biologics regulator, will depart the FDA at the end of April; Sen. Ron Johnson launches an investigation into recent rare disease drug rejections; and Roche and Zealand’s amylin analog fails to match investor expectations—and Eli Lilly’s rival candidate—in a mid-stage trial. Wed, 11 Mar 2026 10:29:25 GMT https://www.biospace.com/fda/prasad-out-at-fda-lawmaker-takes-action-on-rare-disease-rejections-and-a-spate-of-obesity-data https://www.biospace.com/business/rising-amid-flurry-of-car-t-deals-stylus-proves-cell-therapy-is-not-dead Annalee Armstrong Stylus Medicine, a member of BioSpace’s NextGen Class of 2026, launched in May 2025 to develop new, less complex genetic medicines. The company’s in vivo approach has attracted “intense” interest from Big Pharma. Tue, 10 Mar 2026 12:39:51 GMT https://www.biospace.com/business/rising-amid-flurry-of-car-t-deals-stylus-proves-cell-therapy-is-not-dead https://www.biospace.com/business/corsera-eyes-two-pronged-approach-to-tackle-leading-cardiovascular-killer Annalee Armstrong Corsera Health’s Chief Operating Officer Rena Denoncourt and CFO Meredith Kaya speak with BioSpace about the biotech’s mission and vision for the next generation of cardiovascular care. Tue, 24 Feb 2026 11:21:58 GMT https://www.biospace.com/business/corsera-eyes-two-pronged-approach-to-tackle-leading-cardiovascular-killer https://www.biospace.com/business/programmable-rna-2-0-beyond-the-first-mrna-revolution Jennifer C. Smith-Parker BioSpace Insights In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklund, CEO of Circio and Jacob Becraft, Co-founder and CEO of Strand Therapeutics. They discuss how post-COVID, emerging platforms like circular and logic circuit RNA are expanding the field's therapeutic horizons. Thu, 05 Feb 2026 12:03:39 GMT https://www.biospace.com/business/programmable-rna-2-0-beyond-the-first-mrna-revolution https://www.biospace.com/fda/summits-potential-keytruda-rival-gets-november-fda-decision-date Tristan Manalac The FDA is currently reviewing Summit's PD-1/VEGF bispecific as part of a chemotherapy combo for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer. Fri, 30 Jan 2026 12:54:02 GMT https://www.biospace.com/fda/summits-potential-keytruda-rival-gets-november-fda-decision-date